South Korea
· Delayed Price · Currency is KRW KoBioLabs Statistics
Total Valuation
KoBioLabs has a market cap or net worth of KRW 119.15 billion. The enterprise value is 95.04 billion.
| Market Cap | 119.15B |
| Enterprise Value | 95.04B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
KoBioLabs has 19.37 million shares outstanding. The number of shares has increased by 7.78% in one year.
| Shares Outstanding | 19.37M |
| Shares Change (YoY) | +7.78% |
| Shares Change (QoQ) | -10.84% |
| Owned by Insiders (%) | 29.91% |
| Owned by Institutions (%) | 0.29% |
| Float | 13.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.24 |
| PB Ratio | 2.83 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.57 |
| EV / Sales | 1.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.02 |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 27.99.
| Current Ratio | 4.39 |
| Quick Ratio | 4.00 |
| Debt / Equity | 27.99 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.87 |
| Interest Coverage | -11.69 |
Financial Efficiency
Return on equity (ROE) is -16.09% and return on invested capital (ROIC) is -9.61%.
| Return on Equity (ROE) | -16.09% |
| Return on Assets (ROA) | -7.58% |
| Return on Capital (ROIC) | -9.61% |
| Revenue Per Employee | 1.04B |
| Profits Per Employee | -221.91M |
| Employee Count | 50 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 7.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -49.30% |
| 50-Day Moving Average | 7,398.20 |
| 200-Day Moving Average | 8,233.90 |
| Relative Strength Index (RSI) | 31.98 |
| Average Volume (20 Days) | 77,392 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KoBioLabs had revenue of KRW 52.08 billion and -11.10 billion in losses. Loss per share was -585.06.
| Revenue | 52.08B |
| Gross Profit | 34.30B |
| Operating Income | -13.78B |
| Pretax Income | -10.93B |
| Net Income | -11.10B |
| EBITDA | -11.78B |
| EBIT | -13.78B |
| Loss Per Share | -585.06 |
Balance Sheet
The company has 57.63 billion in cash and 16.53 billion in debt, giving a net cash position of 41.10 billion or 2,121.41 per share.
| Cash & Cash Equivalents | 57.63B |
| Total Debt | 16.53B |
| Net Cash | 41.10B |
| Net Cash Per Share | 2,121.41 |
| Equity (Book Value) | 59.06B |
| Book Value Per Share | 2,175.85 |
| Working Capital | 53.88B |
Cash Flow
In the last 12 months, operating cash flow was -10.41 billion and capital expenditures -8.52 billion, giving a free cash flow of -18.93 billion.
| Operating Cash Flow | -10.41B |
| Capital Expenditures | -8.52B |
| Free Cash Flow | -18.93B |
| FCF Per Share | -976.89 |
Margins
Gross margin is 65.86%, with operating and profit margins of -26.45% and -21.30%.
| Gross Margin | 65.86% |
| Operating Margin | -26.45% |
| Pretax Margin | -20.98% |
| Profit Margin | -21.30% |
| EBITDA Margin | -22.62% |
| EBIT Margin | -26.45% |
| FCF Margin | -36.34% |
Dividends & Yields
KoBioLabs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.78% |
| Shareholder Yield | -7.78% |
| Earnings Yield | -9.51% |
| FCF Yield | -15.88% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |